News

October 14, 2019October 14, 2019

Hormone Therapy-Chemo Combo Reduces Risk of Tumor Return in Highly Recurrent Breast Cancer, Phase 3 Trial Shows

News

Using chemotherapy in combination with hormone therapy in women with highly recurring forms of breast cancer reduces the likelihood of disease returning elsewhere in the body over nine years compared with hormone therapy ... Read more

October 9, 2019

Terranea Resort Turns Pink for National Breast Cancer Awareness Month

News

In observance of National Breast Cancer Awareness Month, the Los Angeles oceanfront resort Terranea will again “turn pink” to benefit breast cancer organizations. Throughout October, Terranea will — for the ... Read more

October 7, 2019

Veliparib-Chemo Combo Prolongs Survival Without Disease Progression in Certain Advanced Breast Cancer Patients, Phase 3 Trial Shows

News

Veliparib in combination with chemotherapy significantly prolongs survival without disease progression in women with metastatic HER2-negative breast cancer with BRCA mutations, compared with women on chemotherapy alone, a Phase 3 ... Read more

October 4, 2019October 7, 2019

Verzenio-Faslodex Combo Prolongs Survival of Women with Advanced Breast Cancer, Phase 3 Trial Shows

News

Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative, advanced or metastatic breast cancer who had been treated previously with endocrine therapy, a Phase ... Read more

October 2, 2019

PINKTOBER Events at Hard Rock Promote Breast Cancer Awareness

News

Marking 20 years of support for breast cancer awareness and research, Hard Rock International has kicked off a host of efforts for its annual “PINKTOBER” campaign. Presented every October in observance of ... Read more

September 30, 2019

First Patients Dosed in Phase 1 Trial Testing ARV-471 in Advanced, ER-Positive Breast Cancer

News

The first patients have been dosed in a Phase 1 trial evaluating Arvinas‘ experimental therapy ARV-471 for locally-advanced or metastatic ER-positive, HER2-negative breast cancer. Approximately 80% of newly-diagnosed breast cancers ... Read more

September 27, 2019October 16, 2019

Mylan Launches Generic Version of Faslodex Injection in the US

News

The U.S. Food and Drug Administration has approved Mylan‘s generic version of AstraZeneca‘s Faslodex injection to be used for the same breast cancer indications as the original product, the company ... Read more

September 25, 2019October 7, 2019

For Breast Cancer Awareness Month, Life Image Offering Free Access to Mammosphere App

News

Because access to prior mammograms is critical for women during all stages of breast health, Life Image is offering free membership during October — Breast Cancer Awareness Month — to ... Read more

September 23, 2019

New Herceptin-Perjeta Formulation Shows Promising Safety and Pharmacokinetic Profile, Phase 3 Trial Shows

News

When given together with Herceptin (trastuzumab) at a fixed dose through an under-the-skin (subcutaneous) injection, Perjeta (pertuzumab) reaches levels in the blood in women with HER2-positive breast cancer that is ... Read more

September 20, 2019September 20, 2019

FDA OKs Use of Tool to Predict Patient Response to New Form of Cisplatin in Planned Phase 3 Study

News

The U.S. Food and Drug Administration (FDA) has approved use of a device, called LiPlaCis DRP, that works to predict response to the next-generation investigational chemotherapy LiPlaCis in a planned Phase 3 ... Read more